SQSTM1 and metabolic disease: K67 is a specific inhibitor of the interaction between phosphorylated p62/Sqstm1 and KEAP1, and it suppresses the expression of NRF2 target genes83, making it a potential therapeutic candidate for the treatment of metabolic diseases.